The Substance Abuse and Mental Health Services Administration (SAMHSA) in collaboration with the Ad Council today expanded efforts to continue to provide information, support and resources to individuals and families affected by the Deepwater Horizon oil spill. Emotional distress resulting from traumatic events can surface years after an incident occurs.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/48177/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Millions of U.S. drivers are putting themselves at risk and wasting fuel by failing to properly check tire pressure, according to a new survey by the Rubber Manufacturers Association (RMA).
Only 15 percent of motorists revealed that they know how to correctly check tire pressure. Under inflated tires contribute to more than 600 highway fatalities and 33,000 thousand injuries each year, according to the National Highway Traffic Safety Administration (NHTSA). Additionally, under inflated tires cause U.S. drivers to waste 1.2 billion gallons of fuel annually.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/rma/50200/
“The smallest moments can have the biggest impact on a child’s life. Take time to be a dad today.” That’s the campaign message of new public service advertisements (PSAs) launching today nationwide in recognition of Father’s Day. According to the U.S. Census Bureau, an estimated 24 million children (34%) in the U.S. live apart from their fathers. The PSA campaign is an effort between the U.S. Department of Health and Human Services’ (HHS) Administration for Children and Families, Office of Family Assistance and the Ad Council to show fathers the unique and irreplaceable role they play in their children’s lives.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50580/
The Ad Council is joining the U.S. Department of Agriculture’s Food Safety and Inspection Service, in partnership with the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), to debut their first joint national multimedia public service campaign to help families prevent food poisoning in the home.
The Food Safe Families campaign was announced this morning by USDA Secretary Tom Vilsack and HHS Secretary Kathleen Sebelius in time for the July 4th holiday and the start of summer when foodborne illnesses tend to increase—a time when many families celebrate with food. It’s also a time when foodborne illnesses tend to increase with more outdoor meals, and other factors that increase the risk for disease-causing bacteria in food.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50582/
Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
The 2011 China (International) Urban Development Co-operation and Tourism Destination Brand Marketing Summit was held in Sanya, Hainan province from the 19th to the 22nd of November 2011. This is the first major annual meeting bringing together advertisers in the travel field from both within and outside of China. The event was jointly hosted by the China Association of National Advertisers – Tourism Advertisers Branch, the Hainan Tourism Development Commission and the municipal government of Sanya. Attendees included Gu Xiulian, vice chairman of the standing committee of 10th National People’s Congress of China; Zheng Silin, vice chairman of the Foreign Affairs Committee of the National People’s Congress; as well as representatives from the China National Tourism Administration and from renowned world travel destinations including the Seychelles, Turkey and Mexico. Cui Feng, deputy director of co-organizer Lushan Scenic and Historic Interest Administration Bureau and general manager of Lushan Tourism Development was also in attendance. Mt. Lushan was named at the event as one of the award-winning scenic spots.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53430-china-urban-development-co-operation-tourism-brand-marketing-summit
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
http://www.miraclemulti.com MiracleMulti™ The Best Multivitamins on the market for Men, Women, Vegetarians, and Bodybuilding. Once a day Multivitamin for Health, Energy, Focus, Well Being and Anti-aging.***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
ADP®, a leading provider of human resource outsourcing, payroll, tax, business outsourcing and benefits administration services, and integrated computing solutions for vehicle dealers, today announced that users of its ALINE Card by ADPSM soon can take advantage of the recently introduced ADP Mobile Solutions app to access important information about their payroll and paycard accounts.
Starting in June, when employees register for the ADP Mobile Solutions app, they will be able to view their pay statements, paycard balances and recent transactions—using their iPhones, BlackBerrys or Android smartphones—if their employer receives these services from ADP. Additionally, the app will direct users to the more than 63,000 nationwide ATMnetwork, where they enjoy surcharge-free access to their wages, and to any of the more than 60,000 Green Dot®retailers where a MoneyPak® can be purchased to load cash to their card.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55976-adp-mobile-access-to-aline-card-through-adp-mobile-solutions-app
